CaliciX™ Max, 30mg | Antiviral therapy for severe feline calicivirus, ulcers, bleeding gums

CaliciX™ Max 30 mg is a high-strength systemic antiviral capsule formulated for cats suffering from severe, refractory, or high-viral-load feline calicivirus (FCV) infections, where standard-dose therapy of 15mg is insufficient. 

CaliciX™ Max is designed to support treatment of severe FCV-associated diseases, including:
Severe Oral & Oropharyngeal Disease.
 
Severe Feline Chronic Gingivostomatitis (FCGS)
Caudal Stomatitis with extensive caudal oral inflammation
Ulcerative Stomatitis unresponsive to dental extractions
Deep Lingual Ulceration (Viral Glossitis)
Multifocal Buccal, Labial, and Palatal Ulcers
 
These conditions are characterized by:
Extreme oral pain
Profuse drooling (ptyalism)
Difficulty eating or swallowing (dysphagia)
Weight loss and cachexia
Persistent halitosis and oral bleeding
 
Systemic & Virulent FCV Disease

CaliciX™ Max may be considered in cases with evidence of high systemic viral burden, including:
Virulent Systemic Feline Calicivirus (VS-FCV)
FCV-associated fever and severe lethargy
Facial or limb edema
Lameness
Pulmonary involvement or pneumonia
Hepatic or pancreatic enzyme elevation
Severe inflammatory response with rapid clinical decline
 
Refractory or Relapsing Disease
Cats with persistent FCV shedding
Post-extraction FCGS with incomplete response
Chronic stomatitis with repeated relapse after steroids or immunosuppressive therapy
Large or obese cats requiring higher per-dose antiviral exposure
 
In severe FCV disease, higher systemic concentrations may be required to:
Rapidly reduce viral replication
Suppress ongoing mucosal and systemic viral injury
Support recovery in cats with advanced inflammation and pain
 
This strength supports step-up antiviral therapy while maintaining precise dosing control.

Recommended Dosage
1 capsule every 12 hours for cats below 2.5 kg of body weight.
2 capsules every 12 hours for cats between 2.5 kg to 5 kg of body weight.   
3 capsules every 12 hours for cat above 5 kg of body weight.

Clinical Signs Targeted
Severe oral pain
Drooling (ptyalism)
Dysphagia and anorexia
Oral bleeding and ulceration
Halitosis
Weight loss and cachexia
Fever and systemic inflammation

 Pharmacokinetics
Good oral bioavailability
Rapid systemic absorption
Intracellular activation independent of host viral enzymes
Distribution into oral mucosa, salivary tissues, and inflamed tissues
Predictable exposure without reliance on prodrug conversion

Note: Formal feline PK studies for EIDD-1931 are ongoing; dosing is based on translational data and clinical experience.

Safety & Precautions

Contraindications
Pregnancy or breeding animals
Known hypersensitivity to nucleoside analogues
Use With Caution
Hepatic impairment
Renal disease (especially if combined with NSAIDs)
Long-term use beyond 12 weeks without monitoring
Monitoring Recommendations
CBC every 2–4 weeks during prolonged therapy
Liver enzymes (ALT/AST) if combined with other systemic drugs
Body weight and appetite monitoring
Potential Adverse Effects
Mild gastrointestinal upset
Transient lethargy
Dose-dependent effects with prolonged exposure

Drug Interactions
No known major CYP-mediated interactions
Compatible with:
Analgesics (e.g., buprenorphine)
NSAIDs (with renal monitoring)
Antibiotics for secondary infection
Supportive oral care

Storage
Store below 25 °C
Protect from moisture and light
Keep in original packaging until use


✅ Safe to combine:
Antibiotics (amoxicillin, clindamycin, azithromycin)
Pain medications (buprenorphine, gabapentin)
Appetite stimulants (mirtazapine, maropitant)
Vitamin B12
Probiotics
Most chronic disease medications (thyroid, blood pressure)

⚠️ Use with caution (vet supervision required):
NSAIDs (meloxicam, robenacoxib) – monitor kidney function closely
Steroids (prednisolone, dexamethasone) – can use short-term, but taper as CaliciX™ works
Chemotherapy drugs – potential additive bone marrow suppression
Immunosuppressants (cyclosporine) – may reduce effectiveness of immune response needed to clear virus

❌ Avoid:
Ribavirin (another antiviral) – redundant mechanism, increased toxicity risk
Other experimental antivirals without vet guidance